Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma

NCT01897454 is registered in ClinicalTrials.gov with Albert Einstein College of Medicine as lead sponsor.

NCT NCT01897454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01897454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma
Lead sponsor
Albert Einstein College of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
January 27, 2012
Completion date
November 1, 2021
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, stage iia pancreatic cancer, stage iib pancreatic cancer, stage iii pancreatic cancer